ADScreen, a speech-processing algorithm developed at Columbia Nursing, is now being tested in a clinical trial to see if it can help health care workers identify patients with Alzheimer's earlier.
Lecanemab, marketed as Leqembi, is the first drug for Alzheimer’s disease to receive approval on the basis of clinically slowing the progression of Alzheimer’s disease.
Attending a high school with a high number of teachers with graduate training was the clearest predictor of the impact of school quality on late-life cognition, researchers found.
Columbia Nursing researchers are using AI analysis of voice recordings to find a quick, inexpensive way to screen home care patients for early dementia.
Neurologist Scott A. Small participated in a Kavli Foundation roundtable on the link between the brain's ability to make new cells and age-related memory loss.
A Columbia-led research team has clinically validated a new method for predicting time to nursing home residence or death for patients with Alzheimer’s.